Home LiteratureArticle Details
PMID: 22416052 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations.

Molecular pharmacology ·Vol. 81 ·No. 6 ·2012-06-00 ·Pages 820-31

Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB

Abstract

Although functional selectivity is now widely accepted, the molecular basis is poorly understood. We have studied how aspects of transmembrane region 5 (TM5) of the dopamine D(2L) receptor interacts with three rationally selected rigid ligands (dihydrexidine, dinapsoline, and dinoxyline) and the reference compounds dopamine and quinpirole. As was expected from homology modeling, mutation of three TM5 serine residues to alanine (S5.42A, S5.43A, S5.46A) had little effect on antagonist affinity. All three mutations decreased the affinity of the agonist ligands to different degrees, S5.46A being somewhat less affected. Four functions [adenylate cyclase (AC), extracellular signal-regulated kinase 1/2 phosphorylation (MAPK), arachidonic acid release (AA), and guanosine 5'-O-(3-thio)triphosphate binding (GTPγS)] were assessed. The intrinsic activity (IA) of quinpirole was unaffected by any of the mutations, whereas S5.42A and S5.46A mutations abolished the activity of dopamine and the three rigid ligands, although dihydrexidine retained IA at MAPK function only with S5.42A. Remarkably, S5.43A did not markedly affect IA for AC and MAPK for any of the ligands and eliminated AA activity for dinapsoline and dihydrexidine but not dinoxyline. These data suggest that this mutation did not disrupt the overall conformation or signaling ability of the mutant receptors but differentially affected ligand activation. Computational studies indicate that these D(2) agonists stabilize multiple receptor conformations. This has led to models showing the stabilized conformations and interhelical and receptor-ligand contacts corresponding to the different activation pathways stabilized by various agonists. These data provide a basis for understanding D(2L) functional selectivity and rationally discovering functionally selective D(2) drugs.

MeSH Terms
Animals CHO Cells Cricetinae Cricetulus Guanosine 5'-O-(3-Thiotriphosphate)/metabolism Ligands Mutation Protein Conformation Radioligand Assay Receptors, Dopamine D2/chemistry,genetics,metabolism Serine/metabolism
Chemicals
Ligands Receptors, Dopamine D2 dopamine D2L receptor Guanosine 5'-O-(3-Thiotriphosphate) Serine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Fowler J Corey
Division of Medicinal Chemistry and Toxicology Curriculum, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Bhattacharya Supriyo
Urban Jonathan D
Vaidehi Nagarajan
Mailman Richard B
References (45)
45 references, click to expand
  1. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.
    J Biol Chem. 1989 Aug 15;264(23):13572-8 PMID: 2547766
  2. The role of conformational ensembles of seven transmembrane receptors in functional selectivity.
    Curr Opin Pharmacol. 2010 Dec;10(6):775-81 PMID: 20933468
  3. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1.
    J Comput Aided Mol Des. 2010 Aug;24(8):659-74 PMID: 20512399
  4. Site-directed mutagenesis of the human dopamine D2 receptor.
    Eur J Pharmacol. 1992 Oct 1;227(2):205-14 PMID: 1358663
  5. trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
    J Med Chem. 1990 Jun;33(6):1756-64 PMID: 1971308
  6. The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.
    Nature. 2011 Jan 13;469(7329):241-4 PMID: 21228877
  7. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists.
    J Biol Chem. 2005 Jun 10;280(23):22165-71 PMID: 15817484
  8. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.
    J Pharmacol Exp Ther. 2002 Jun;301(3):1179-89 PMID: 12023553
  9. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors.
    J Neurochem. 1992 Aug;59(2):627-35 PMID: 1321233
  10. Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
    J Med Chem. 1989 Sep;32(9):2050-8 PMID: 2527994
  11. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms.
    Bioorg Med Chem. 2004 Mar 15;12(6):1403-12 PMID: 15018913
  12. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor.
    J Am Chem Soc. 2010 Apr 14;132(14):5205-14 PMID: 20235532
  13. Cyclic coordinate descent: A robotics algorithm for protein loop closure.
    Protein Sci. 2003 May;12(5):963-72 PMID: 12717019
  14. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist.
    Eur J Pharmacol. 1997 Mar 26;323(1):27-36 PMID: 9105873
  15. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
    J Mol Biol. 2008 Oct 3;382(2):539-55 PMID: 18638482
  16. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor.
    J Biol Chem. 2001 Jul 6;276(27):24433-6 PMID: 11320077
  17. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.
    Mol Pharmacol. 1998 Jul;54(1):94-104 PMID: 9658194
  18. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution.
    J Cyclic Nucleotide Res. 1975;1(4):207-18 PMID: 177461
  19. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states.
    Mol Pharmacol. 2004 Jul;66(1):97-105 PMID: 15213300
  20. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations.
    Mol Pharmacol. 1998 Aug;54(2):435-44 PMID: 9687586
  21. Functional selectivity through protean and biased agonism: who steers the ship?
    Mol Pharmacol. 2007 Dec;72(6):1393-401 PMID: 17901198
  22. Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation.
    Biophys J. 2008 Mar 15;94(6):2027-42 PMID: 18065472
  23. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop.
    Annu Rev Pharmacol Toxicol. 2002;42:437-67 PMID: 11807179
  24. Satisfying hydrogen bonding potential in proteins.
    J Mol Biol. 1994 May 20;238(5):777-93 PMID: 8182748
  25. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
    Neuropsychopharmacology. 1999 Jun;20(6):612-27 PMID: 10327430
  26. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
    Mol Pharmacol. 2005 Oct;68(4):1039-48 PMID: 15985612
  27. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein.
    Biochem J. 2000 Sep 15;350 Pt 3:717-22 PMID: 10970784
  28. An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors.
    Mol Pharmacol. 2009 Jan;75(1):19-26 PMID: 18820126
  29. Modeller: generation and refinement of homology-based protein structure models.
    Methods Enzymol. 2003;374:461-91 PMID: 14696385
  30. GPCR functional selectivity has therapeutic impact.
    Trends Pharmacol Sci. 2007 Aug;28(8):390-6 PMID: 17629962
  31. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
    J Med Chem. 1996 Jan 19;39(2):549-55 PMID: 8558526
  32. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor.
    Mol Pharmacol. 2011 Mar;79(3):575-85 PMID: 21163968
  33. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
    Trends Pharmacol Sci. 1995 Jul;16(7):232-8 PMID: 7667897
  34. Functional selectivity and classical concepts of quantitative pharmacology.
    J Pharmacol Exp Ther. 2007 Jan;320(1):1-13 PMID: 16803859
  35. Investigation of the role of conserved serine residues in the long form of the rat D2 dopamine receptor using site-directed mutagenesis.
    J Neurochem. 1996 Jan;66(1):394-402 PMID: 8522980
  36. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Neuropsychopharmacology. 2003 Aug;28(8):1400-11 PMID: 12784105
  37. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.
    Eur J Pharmacol. 1989 Jul 4;166(1):111-3 PMID: 2572425
  38. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.
    J Pharmacol Exp Ther. 2002 Jun;301(3):1166-78 PMID: 12023552
  39. Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist.
    Neuropsychopharmacology. 1991 Nov;5(3):187-95 PMID: 1684499
  40. A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding.
    Mol Pharmacol. 2009 Jan;75(1):113-23 PMID: 18809670
  41. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
    Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 PMID: 4202581
  42. Rapid, semi-automated, and inexpensive radioimmunoassay of cAMP: application in GPCR-mediated adenylate cyclase assays.
    J Neurosci Methods. 2009 Mar 15;177(2):261-6 PMID: 19007813
  43. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor.
    Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9276-81 PMID: 8799191
  44. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
    J Med Chem. 1996 Jan 5;39(1):285-96 PMID: 8568818
  45. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
    J Pharmacol Exp Ther. 2001 Feb;296(2):338-44 PMID: 11160615
Article Info
Journal
Molecular pharmacology
Abbr.
Mol Pharmacol
ISSN
1521-0111
Published
2012-06-00
Epub
2012-00-13
Pages
820-31
Language
English
Region
United States
NLM ID
0035623
PMCID
PMC3362898
Subset
IM
Grants
NIMH NIH HHS · R01 MH040537 · United States
NIMH NIH HHS · U19 MH082441 · United States
NIMH NIH HHS · MH040537 · United States
NIMH NIH HHS · MH082441 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com